2020
DOI: 10.1124/jpet.120.000309
|View full text |Cite
|
Sign up to set email alerts
|

Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
16
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 15 publications
(17 citation statements)
references
References 35 publications
(52 reference statements)
1
16
0
Order By: Relevance
“…autophagy dependent MDA-MB-231 and MDA-MB-468 tumors compared to autophagy independent MCF7 tumors (Maycotte et al, 2014) (Figure 4A), suggesting that autophagy dependent tumors sequester more HCQ over time. This could be due to an increase in lysosomes in autophagy dependent tumors compared to autophagy independent tumors (Collins et al, 2021). There are important implications of this when considering dual treatment with HCQ and other drugs, especially chemotherapies that sequester in lysosomes.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…autophagy dependent MDA-MB-231 and MDA-MB-468 tumors compared to autophagy independent MCF7 tumors (Maycotte et al, 2014) (Figure 4A), suggesting that autophagy dependent tumors sequester more HCQ over time. This could be due to an increase in lysosomes in autophagy dependent tumors compared to autophagy independent tumors (Collins et al, 2021). There are important implications of this when considering dual treatment with HCQ and other drugs, especially chemotherapies that sequester in lysosomes.…”
Section: Discussionmentioning
confidence: 99%
“…Given that AUC0-inf are not dose proportional from 40 to 80 mg/kg and clearance is concurrently increasing, this signifies non-linear PK with less drug in the blood at higher HCQ concentrations. A potential explanation is an increase in cellular lysosomal volume associated with lysosomal biogenesis triggered by HCQ (Collins et al, 2021) leading to an increase in tissue uptake and subsequent lower blood levels. This explanation is supported by the relationship between dose and AUC for blood vs. tissues where whole blood shows a 1.80 and 3.07fold increase in AUC when doses are increased 2 and 4-fold whereas tissues (brain, gut, kidney and liver) all show fold increases greater than 2 and 4 with averages of 2.47± 0.28 and 4.78 ± 0.71.…”
Section: Hcq Exposure Is Dose Dependent In Vivomentioning
confidence: 99%
“…Cell lines such as Vero (ATCC® CRL-1586™)—a monkey kidney epithelial cell line with a cell diameter of 17 μm—are usually cultured in a two-dimensional environment by completely soaking the cells in a cell culture medium containing the compound of interest. To simulate the kinetics of compound uptake, we assumed the Vero cell lysosomal volume to be 1% of its cellular volume and in the same order of magnitude as that in other cell lines [ 25 , 49 ]. The extracellular CQ and HCQ concentrations in the Vero cell line simulations were set to be constant, because bulk concentration changes were assumed to be minimal as well as in order to eliminate the dependence on differences in intracellular lysosomal volume (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…4A and D ). For example, in cells lines, the lysosomal volumes are 0.5% of the cell volume in MCF7, 0.8% in MDA-MB-231, 1.4% in T47D, and 3.7% in MDA-MB-468 cells [ 49 ]. The human respiratory tract is lined with different cell types—such as goblet cells, club cells, fibroblasts, epithelial, and macrophages—and their expression varies in different regions of the lungs.…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, the anti-infective, immunosuppressive agent hydroxychloroquine, sometimes used to counter treatment induced rashes, is reported to have lysosomotropic activity and thus might reduce treatment efficacy when co-administered with any basic drug, including CDK4/6 inhibitors. 60 Recent studies of lysosomotropism-mediated doxorubicin resistance in angiosarcoma cells suggest that this potential resistance mechanism can be countered by treating with the beta adrenergic receptor (beta-AR) antagonist propranolol, which acts through a beta-AR-independent mechanism to increase cytoplasmic doxorubicin concentrations and decrease lysosomal accumulation. 61…”
Section: Discussionmentioning
confidence: 99%